talampanel
Term · Oncology and biomedicine · MLC-T-ONC-008502
A substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity. Talampanel noncompetitively binds to the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.
| Identifier | MLC-T-ONC-008502 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | LY 300164 |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-008502",
"term": "talampanel",
"field": "Oncology and biomedicine",
"definitions": [
"A substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.",
"A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity. Talampanel noncompetitively binds to the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury."
],
"synonyms": [
"LY 300164"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/talampanel/"
}
Record 15,961 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.